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Objective: This study explored patient recall of clinician presentation of information about prescription
medication, looking speciﬁcally for communication patterns and differences by patient individual
characteristics and by medication availability type.
Methods: A cross sectional survey collected information about 216 patients’ perceptions of clinician
presentations of medication information.
Results: Demographically, males recalled receiving more information about reasons, risks, and regimen
in medication discussions. By medication type, patients reported receiving more medication information
when the clinician presented a prescription-only medication as opposed to a medication that was also
available over the counter.
Conclusion: Given the broad and unmonitored use of over-the-counter products, coupled with the
increasing awareness of risks associated with many of these medications, it is concerning that patients
report receiving less information about these products.
Practice implications: The emphasis on appropriate medication counseling should not be limited to
medications available only by prescription. Prescribers should be mindful of these potential tendencies
when discussing medications.
Published by Elsevier Ireland Ltd.
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1. Introduction
Clinician counseling about medication can improve patient
understanding of medication instructions and adherence to those
instructions [1,2]. However these discussions can often be overlooked due to the routine and frequent nature of prescribing
medicine. Research shows that during the average 15.9 min of a
patient visit, only 49 s addressed factors regarding a new
prescription [3]. In these discussions, as few as 33% of patients
receive verbal counseling regarding the side effects of a new
prescription [4], and patients who receive less counseling about
new medication are less likely to adhere to medication regimens
[5,6]. In addition to risk information, research supports presenting
medication name, directions for use, reason for medication, and
duration of use in medication prescription discussions [7–10].
Previous studies show that patient adherence to medication
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instructions are determined proximally by their perceived need for
the medication, their understanding/response to side effects, and
the cost of the medication [11]. Distally, the clinician affects
medication commitment and medication concerns through the
prescription discussion [12].
While many physicians may defer appropriate counseling of
these risks and effects to other resources, there is evidence that
other means of patient education have less impact. Patients trust
physicians and select them as their preferred source of health
information [13,14], speciﬁcally prescription information [7,15]. In
The Netherlands, one study showed that 66% of patients perceived
the prescribing clinician to be the primary source of information
about their medication [16]. Additionally, clinician counseling
regarding risks generates higher patient awareness than pharmacist counseling or written educational materials [17]. Studies show
that patients struggle with reading drug labels and provided
instructions [18,19].
Previous research has shown these gaps in clinical practice
regarding general medication discussions; however, it is not
known if these gaps exist across medication types. Of particular
interest here is whether the prescribed medication is also available
in an over-the-counter (OTC) formula. Generally, due to the
widespread use and easy availability, some OTC pain medications,
such as nonsteroidal inﬂammatory drugs, are assumed by patients
This article is a U.S. government work, and is not subject to copyright in the United States.
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Table 1
Risks, reasons, and regimen in medication discussions index (R3iMeDi).
Determinant

Item

Potential rangea

Risks

The healthcare provider told me today about the risks or side effects of the medication
The healthcare provider told me today about the long-term safety concerns of taking the prescribed medication.

1–5
1–5

Reasons

The healthcare provider explained the reason for prescribing this medication today.
The healthcare clearly explained the beneﬁts of my prescribed medication.

1–5
1–5

Regimen

The healthcare provider gave clear instructions on how to take the prescribed medication, such as how much and when.
The healthcare provider explained what other medications could interfere with how this medication works.

1–5
1–5

R3iMeDi
a

6–30

Higher values indicate positive value.

to be benign [20,21]. In stark contrast to this widespread
perception, there is robust evidence that these medications can
carry clear and signiﬁcant risks, to include gastrointestinal injury/
bleeding, renal complications, and cardiovascular injury [22,23].
The morbidity and mortality impact of these effects is becoming
better deﬁned. In a European study, 30% of hospitalizations for
adverse reactions to medications were related to NSAID use [24].
Multiple large studies have well described the degree of impact
that these medications on the organ systems as described above, as
well as serving to complicate numerous comorbidities, such as
hypertension, congestive heart failure, and asthma [25,26].
However, multiple studies have shown that generally patients
are not aware of these risks [21]. While this lack of awareness
might be understandable with OTC formulations, it is more
concerning that patients seem similarly uninformed about these
risks when they are prescribed these medicines [27]. This study
aims to explore if there are differences in how patients recall
medication discussions they have with their clinicians when the
clinician prescribes a prescription-strength formulation of an OTC
medication.
This study explored patient recall of clinician presentation of
information about new prescriptions, looking speciﬁcally for
communication patterns and differences.
The following questions were examined in this study:
Research question 1: How do patient-reported medication
discussions differ by patient characteristics (age, gender,
education, and health status)?
Research question 2: How do patient-reported medication
discussions differ by availability type (whether a prescribed
medication is also available in an OTC formulation or not)?
2. Methods
This is a cross-sectional survey design. After receiving
Institutional Review Board approval, a research station, manned
by the ﬁrst author and a research associate, was set up in the
waiting room of a community hospital pharmacy in the
metropolitan Washington, DC, area for two weeks in summer
2012. Screening was conducted verbally prior to consent and
included three criteria: age greater than 18, had an appointment
with their clinician, and was waiting for a new (not reﬁll)
prescription.
When volunteers met screening criteria, a research team
member launched the survey on a tablet computer for the
participant. For volunteers who were uncomfortable with the
tablet, an identical paper-and-pencil version was available.
Participants received a canvas bag as a participation incentive.
The primary outcome of interest was patient-reported recall of
if the clinician presented the risks, reasons, and regimen in the new
prescription medication discussion. This outcome was measured
by an index that included six items intended to assess recall of the
determinants of medication adherence, the risks, reasons, and

regimen in medication discussions index (R3iMeDi). Table 1
presents the individual items and representative determinants.
The items were summed to create an index that ranged from 6 to
30, where high scores indicate positive discussion. When data was
missing from one of the individual index items, the case was not
included in index analyses, but was retained in individual item
analyses.
These items were developed with the intent to assess the
patient’s recall of the clinician’s information about the medication
only, not the patient’s cognitive representation of the prescribed
medication or medication in general. However, the items here
assess recall of information that can inform patient beliefs. Similar
to the Beliefs about Medication Questionnaire subscales, the items
here assess patient recall about how the clinician gave information
that communicates the necessity of the speciﬁc medication and the
concerns of the speciﬁc medication [28].
Principal component factor analysis with Varimax rotation was
used to conﬁrm the factor structure. The criterion for factor
extraction was an Eigen value > 1.0.
For research question 1, individual level variables (age,
gender, education, ethnicity, health status) were predictor
variables. For research question 2, the predictor variable was
medication type. The survey asked patients, ‘‘Did you receive a
prescription today? If so, please list one.’’ They were then
prompted to respond to R3iMeDi items with the following
prompt, ‘‘The following questions ask about the conversation
you had with the healthcare provider about this medication he or
she prescribed for you today.’’ The second author coded patientreported medication names by availability type: prescription
that is also available in an over-the-counter version or available
only as a prescription.
Two variables were included as potential covariates of
medication discussions: communication satisfaction and patient
activation. The adapted communication satisfaction scale [29]
included four Likert-type items (measured 1–5) assessing patient
perception of clinician communication behaviors including respect, listening, response to patient needs, and time to ask
questions. Patient activation is a speciﬁc type of involvement in
which patients recognize that they are responsible for their own
care, which motivates them to seek health-related information and
manage their own health [30]. For this study, patient activation
was assessed with the licensed patient activation measure [31],
which uses 13 Likert-type items to create a continuous patient
activation measure on a scale of 0–100.
Participants also reported age, gender, ethnicity, education,
overall health status [32], and clinic from which the medication
was prescribed, to include family medicine, internal medicine, and
other.
Quantitative analyses were conducted using the SPSS Version
19.0. Tests of statistical signiﬁcance were set at a pre-determined
alpha level of 0.05 (two-tailed). Relationships between continuous
independent variables and recall were assessed with correlation
testing. Relationships with nominal independent variables were
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Analysis

Recruitment

Assessed for eligibility (n= 335)

Excluded (n= 119)
¨ Not meeting inclusion criteria (n= 29)
¨ Declined to participate (n= 90)

Fig. 1. Flow diagram of recruitment and participation.

assessed with analysis of covariance (ANCOVA). The covariate
nature also allows for the statistical control of design-uncontrolled
variables; included here are patient activation and communication
satisfaction.
3. Results
Of 335 patients assessed for eligibility, 216 (64.48%) completed
the survey. Fig. 1 presents a diagram of recruitment and
participation. Table 2 presents sample characteristics.
The R3iMeDi index had strong internal reliability (Cronbach’s
a = 0.899). Principal component factor analysis indicated unidimensionality of the index (a single dimension emerged, eigenvalue
of 4.039, explaining 67.31% of the variance). The R3iMeDi mean
was 23.92 (5.46). The communication satisfaction scale also had
strong reliability (a = .950). The mean was 4.47 (0.96), and the
mean for patient activation was 73.77 (15.53).
3.1. Research question 1
At the individual level, there was not a difference in R3iMeDi by
age, education, ethnicity, or health status. However, for gender
differences, an analysis of covariance (ANCOVA), controlling for
communication satisfaction and patient activation, showed that
males recalled receiving more information in medication discussions (M = 25.60 (sd 0.62) than females (M = 23.10 (sd 0.42)), F (1,

4.50
4.00

4.07
(.15)
3.59
(.10)

3.50

184) = 11.14, p < 0.001, partial h2 = 0.06. The covariates, patient
activation, F (1, 184) = 38.87, p < 0.001, and communication
satisfaction, F (1, 184) = 8.86, p < 0.01, also had a signiﬁcant
association with R3iMeDi.
To further explore differences, the ANCOVA was repeated on the
six individual items. Males consistently reported receiving more
information regarding side effects, long-term safety, reasons for
medication, beneﬁts of medication, and potential medication
interactions. See Fig. 2 for estimated marginal means.
3.2. Research question 2

Analysed (n= 216)
¨ Excluded from research question 2 analysis (did not recall
medication name) (n= 39)

4.63
(.10)4.39
(.07)

5.00
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3.92
(.16)
3.37
(.11)

Only patients who were able to recall the name of the
prescribed medication were included for analysis. Of the 216
patients who completed the survey, 177 (81.94%) were able to
recall the name of the medication prescribed by the clinician.
The group of patients who recalled the name of the medication
was not signiﬁcantly different than patients who did not recall
medication name, by age, gender, ethnicity, health status, or
patient activation. However, patients who listed the prescribed
medication name reported a higher level of education than
those who did not list a speciﬁc medication when prompted, F
(1, 213) = 7.77, p < 0.01. Only patients who recalled medication
name were included for analysis, to enable coding for
medication type.
For research question 2, an ANCOVA was calculated with the
independent variable medication types, and the covariates patient
activation and communication satisfaction, as determinants of
recall of information received. For availability type, 53 medications
were also available over the counter and 103 were available only
by prescription.
In the ANCOVA, the covariates patient activation, F (1,
148) = 16.44, p < 0.001, and communication satisfaction, F (1,
148) = 7.57, p < 0.01, again had a signiﬁcant association with
R3iMeDi. When controlling for these covariates, there was a
signiﬁcant relationship between availability type and R3iMeDi, F
(1, 148) = 12.27, p < 0.001, partial h2 = 0.08, in which patients
recalled receiving more information when discussing prescriptiononly medication (M = 24.82 (sd 0.48)) as compared to medications
that are also available over the counter (M = 21.91 (sd 0.68)).
To further explore differences within availability type, the
ANCOVA was replicated with each of the six individual index items.
In these analyses, discussion regarding medication risks and

4.45
(.11)4.14
(.08)

4.45
(.12)4.26
(.08)

4.01
(.15)
3.35
(.10)

3.00

Male

2.50

Female

2.00
1.50
1.00
Side eﬀects‡

Long-term
safety‡

Reasons*

Beneﬁts*

Instrucons

Interac ons‡

Fig. 2. Patient-reported index items of risks, reasons, and regimen in medication discussions index (R3iMeDi) by gender (estimated marginal means and standard errors).
y
p < 0.001, *p < 0.05
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Table 2
Sample characteristics (N = 216).

n

% of N

Gender

Female
Male

150
66

30.6
69.4

Ethnicity

White/Caucasian
Black or African-American
Asian/South Paciﬁc
Hispanic
Native American/Alaska Native
Choose not to respond

122
51
15
15
3
10

56.5
23.6
6.9
6.9
1.4
4.7

Education

Less than high school
High school or equivalent
Some college, no degree
Associate degree
Bachelor’s degree or more

1
15
50
32
117

0.5
6.9
23.1
14.8
54.2

Health status

Poor
Fair
Good
Very good
Excellent

6
31
88
72
19

2.8
14.4
40.7
33.3
8.8

Clinic seen

Family medicine
Internal medicine
Other

44
46
93

20.4
21.3
43.1

Age

Mean (s.d.)
48.35 (15.48)

regimen remained signiﬁcant by availability type. Patients recalled
receiving more information for risks and regimen in discussions
about medications available only by prescription. See Fig. 3 for
estimated marginal means.
4. Discussion and conclusion
4.1. Discussion
The results provide insight into differences in patient recall of
clinician communication patterns regarding new prescriptions. At
the individual level, differences emerged by gender. Since this
study controlled for communication satisfaction and patient
activation, differences by gender do not appear to be a factor of
involvement in healthcare or satisfaction with the clinician, which
contradicts Street’s proposition that active participation in a
consultation can erase communicative behaviors arising from

5
4.5
4
3.5

3.97
(.11)
3.30
(.16)

4.55
4.31(.07)
(.10)
3.81
(.12)

gender stereotypes [33]. This ﬁnding may be interpreted as a result
of the gendered approach to clinical communication in which
males take an instrumental approach to the encounter, focusing on
the biomedical issue, and thus may recall receipt of more
information [34]. This is particularly salient in the context of
medication prescription, which likely focuses on the biomedical
context as opposed to clinical interactions that could address more
psychosocial issues.
Another research ﬁnding that could affect this difference in
perceived information receipt could be a result of the amount of
information desired. Previous research shows that female patients
received less information than they wanted from their clinician
[35]. Results here may be attributed to women perceiving less
medication information because of higher information needs.
Clinicians need to assess patient expectations for medication
information to ensure they are providing the level of information
the patient wants.

4.30
4.06(.09)
(.13)

4.43
(.09)
4.01
(.13)

3.74
(.12)
3.13
(.16)

3.08
(.17)

3

OTC
Rx-only

2.5
2
1.5
1
Side eﬀects†

Long-term
safety†

Reasons

Beneﬁts

Instruc ons‡ Interac ons‡

Fig. 3. Patient-reported index items of risks, reasons, and regimen in medication discussions index (R3iMeDi) by availability type (estimated marginal means and standard
errors). yp < 0.001, zp < 0.01
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When considering medication type, differences emerged in
discussions about prescribed medications that are prescription
only and those that are also available to patients over the
counter. Signiﬁcant differences were seen in 4 of 6 items of
medication counseling quality. These differences persisted
even when controls for variables of patient satisfaction with
clinician communication and patient activation were introduced. These factors have been shown to impact the degree of
retention of information [36], participation in decision making
[37], and medication adherence [38]. To some degree, this
difference with medications also available over the counter is
not surprising. This may well reﬂect a general sense on the part
of both clinicians and patients that for medications to be
available over the counter, there is an intrinsic degree of safety
that allows a more relaxed or minimized approach in
discussing risks and side effects. This result is similar to
research ﬁndings that discussions about dietary supplements
are suboptimal regarding risk [39].
This investigation focused on the immediate patient perspective after receiving a new medication prescription. By
collecting data in the pharmacy setting, the study leverages the
time period in which a patient has been exposed to the clinician’s
information but not yet the pharmacist’s input. This allows for
more accurate recall of information delivered by the clinician,
and minimizes potential confounding factors such as selfdirected inquiry, pharmacist counseling, etc. A second strength
to this study design is the approach to practice-based research in
the pharmacy setting, wherein the population reﬂects a range of
specialty and clinic types.
The study is limited by its reliance on self-reported data,
allowing for potential self-selection and social desirability bias.
Patient recall in self-report surveys continues to be a challenge;
however, two-thirds of patients recall the information given upon
prescription [6].
As there were not external measures of quality such as thirdparty review or clinician self-assessment applied to these
discussions, it is challenging to determine the impact of these
ﬁndings in a broader clinical sense. Future research could replicate
study methods using a different measure of medication information such as the Satisfaction with Information about Medicines
Scale [40], which includes the patient’s perception of how much
information he or she needs about the medication. Additionally,
generalizability of results is limited by the single-site nature of this
study.
In patient-level analyses, a potential confounder may have
been the patient’s perception of similarity with the doctor.
Previous research has shown that when patients perceive the
doctor to be similar to themselves they are more likely to be
active participants, be more satisﬁed with care, express
greater trust, and have a stronger intention to adhere to
recommendations [41]. However, this study did not assess
patient perception of clinician similarity. Another limitation,
particularly regarding gender differences, is that this study
did not record the gender of the clinician, which can also
inﬂuence the communication interaction, particularly gender
concordance [42].
4.2. Conclusion
Receiving initial risk messages from the clinician increases the
potential for message repetition and retention through pharmacy
and health educator interactions and materials [6,7]. The observed
differences show a disparity in perceived medication discussions
by gender and by medication availability, whether they are
available by prescription only or are also available without a
prescription. Given the broad and unmonitored use of OTC
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products [43], coupled with the increasing awareness of risks
associated with many of these medications [44–46] the switching
from prescription to over-the-counter availability [47,48], and the
potential for overuse [49,50], this ﬁnding is notable.
4.3. Practice implications
The emphasis on appropriate medication counseling should
not be limited to medications available only by prescription.
Prescribers should be mindful of these potential tendencies
when discussing new medications. Results indicate a need for
clinicians to present safety messages about OTC medication,
including instructions, side effects, long-term safety, and
potential interactions.
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